Geode Capital Management
PHAS

Geode Capital Management’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Geode Capital Management’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-320,642
Closed -$56K – 5049
2022
Q3 		$56K Hold
320,642
– – ﹤0.01% 4743
2022
Q2 		$192K Hold
320,642
– – ﹤0.01% 4293
2022
Q1 		$423K Buy
320,642
+40,239
+14% +$65.2K ﹤0.01% 4024
2021
Q4 		$731K Sell
280,403
-186
-0.1% -$562 ﹤0.01% 3858
2021
Q3 		$872K Buy
280,589
+84,729
+43% +$283K ﹤0.01% 3750
2021
Q2 		$728K Sell
195,860
-45,653
-19% -$152K ﹤0.01% 3757
2021
Q1 		$835K Buy
241,513
+9,477
+4% +$38.5K ﹤0.01% 3627
2020
Q4 		$779K Sell
232,036
-4,156
-2% -$14.9K ﹤0.01% 3444
2020
Q3 		$829K Buy
236,192
+10,258
+5% +$41.3K ﹤0.01% 3277
2020
Q2 		$1.04M Buy
225,934
+11,275
+5% +$49.9K ﹤0.01% 3125
2020
Q1 		$710K Buy
214,659
+24,942
+13% +$114K ﹤0.01% 3151
2019
Q4 		$1.16M Buy
189,717
+7,371
+4% +$30.4K ﹤0.01% 3226
2019
Q3 		$760K Buy
182,346
+251
+0.1% +$2K ﹤0.01% 3331
2019
Q2 		$2.39M Buy
182,095
+105,791
+139% +$1.3M ﹤0.01% 2834
2019
Q1 		$725K Buy
+76,304
New +$302K ﹤0.01% 3289

Other funds holding PHAS

DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
HLA
Hamilton Lane Advisors Conshohocken, Pennsylvania $149M AUM 14.17% 1-Year Est. Return
IIA
IPG Investment Advisors San Diego, California $582M AUM 33.22% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Geode Capital Management's PHAS Position: Q4 2022 in Review

Geode Capital Management sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q4 2022, closing a stake of 320,642 shares — an estimated $56K sold.

Geode Capital Management first reported a position in PHAS in Q1 2019 and held it in 15 quarters. The position peaked at $2.39M in Q2 2019. 5 funds tracked by Wall St. Rank hold PHAS as of Q4 2022.

  • Geode Capital Management reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Geode Capital Management sold 320,642 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $56K.
  • Geode Capital Management first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q1 2019 and held it in 15 quarters.
  • Geode Capital Management's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $2.39M in Q2 2019.
  • 5 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on Geode Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.